drugset
drugset / Trial / NCT00917891

An Expanded Safety Study of Dapivirine Gel 4759 in Africa

NCT00917891 ↗

Phase 1/2 Completed 280 enrolled International Partnership for Microbicides, Inc.
RandomizedParallel-groupTriple-blindPrevention

Summary

The purpose of this study is to determine whether dapivirine gel 4759 is safe for daily use by healthy women in Kenya, Malawi, Rwanda, South Africa and Tanzania.

Timeline

Start
2009-11
Primary completion
2011-01
Completion
2011-09

Drugs

EvaluationDrugModalityDoseRoute
Subject dapivirine Small molecule 1.25 mg Other

Indications

AIDS